7月3日 - ** 摩根士丹利开始对药物开发软件商 Certara CERT.O进行评级，评级为 "等权重"。
** 公司的重点是生物仿真，Certara的平台旨在优化药物设计和测试。
** 摩根士丹利称，CERT 拥有市场领先的平台，经常性收入强劲，交叉销售机会巨大
** 券商预测值保持不变，仍为 16 美元，比该股上次收盘价上涨约 39.3
** 11家券商中有5家将该股评级为 "买入 "或更高，6家为 "持有"；其PT中值为16美元--LSEG数据
** 截至上次收盘，该股今年累计上涨 ~7.9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.